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Background: Immunosuppression in breast cancer has been reported in women and in the highly metastatic mouse
mammary tumor model 4 T1. The immunosuppressive environment complicates the use of the humoral response
against the tumor as an immunodiagnostic tool. IgM has not been used in immunodiagnostic in part because its
antitumor responses, both innate and adaptive, have not been studied in function of time in breast cancer.
We show a new approach to analyzing the mouse humoral immune response, and compare the evolution with time
of IgG and IgM responses against the antigens of 4 T1 cells.
Methods: The study is based on 2-dimensional immunoblotting detection of antigens from 4 T1 cells by the IgG and
IgM antibodies in the serum of female mice injected with 4 T1 cells.
Results: There was a high variability in the intra-and inter-mouse response. Variability in the IgM response was manifested
as a pattern of spots that could become a multibinomial variable of 0 and 1, which could represent a signature
of the immune response. Different numbers of spots was found in the IgG and IgM responses from week 1 to 5. On
average, the IgM had more but the IgG response decrease with the time. The natural IgM at t = 0 responds stronger
than w1; the adaptive response of both IgM and IgG were elicited where, with the former being stronger better than
the latter. Antigens that are recognized by some female mice in the first week are also recognized by other female mice
at time 0. Contamination of the natural IgM makes difficult use the adaptive IgM as a tool for immunodiagnostic.
Conclusions: IgM and IgG response varied with the time and individuals. Spot variation in 2D pattern for the natural
IgM could be expressed as a binomial signature, which opens up the way to correlate a particular pattern with
resistance or susceptibility. This uncovers a battery of IgMs for each individual to confront cancer or infections. The
possibility to differentiate between adaptive IgM antibodies from the natural IgM will allow investigation of the
adaptive IgM for early immunodiagnosis.
Keywords: 2D Immunoblot, IgM, 4 T1 cells, Mammary carcinomaBackground
During a lifetime, human beings are permanently exposed to
the development of transformed cells, which arise sponta-
neously or by contact with trigger factors. Immune surveil-
lance of cancer leads to the generation of anti-tumor
antibodies from the early stages of the disease [1]. Once a
tumor is established, however, the network of immune sys-* Correspondence: postoa@unam.mx
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diumtem associated with it, may paradoxically promote tumor
growth and metastasis rather its destruction [2].The use of
mouse models allows investigation of how the immunosup-
pression status may contribute to tumor establishment. Im-
munosuppression in breast cancer occurs in women [3-5],
and in the highly metastatic mouse mammary tumor model
4 T1 [6,7]. An immunosuppressive environment complicates
the use of the humoral response against the tumor as an im-
munodiagnostic tool. Autoantibodies have many attractive
features as biomarkers, in particular natural IgM antibodies
(Ab) are involved in the primary defense mechanism that ac-
tivates the cascades of complement and apoptosis. ThereforeCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and elimination of transformed cells as part of the innate
humoral immune system [8-12]; IgMs are low-affinity anti-
body products of the innate immunity that detect the major
changes on malignant cells as post-transcriptional modifi-
cations of carbohydrate patterns [9,13-18]. Natural IgM anti-
bodies can induce tumor-specific apoptosis [19]. The IgM
antitumor responses, both innate and adaptive, have not
been studied as a function of time in breast cancer, and
therefore we show a new approach for analyzing the mouse
humoral immune response, and compare the evolution of
IgG and IgM responses against the antigens of 4 T1 cells.
The study is based on the detection of antibodies in the
serum of female mice injected in the mammary gland nipple
with 4 T1 cells, with analysis by two-dimensional immuno-
blotting. Differential behavior was found between the re-
sponses of IgG and IgM. Not only the response to IgG, but
the response of IgM decreased with the time, although with
different kinetics. Each mouse has an individual pattern of
recognition, in our experiments to a tumor antigenic back-
ground and a variable number of spots for IgMs. In other
words, each individual has a particular expression of IgMs
(in number and capacity of recognition) that is genetically
determined. This variability was measured by generating a
signature expressed as a binomial variable. The ability to dif-
ferentiate between the adaptive IgM and natural IgM anti-
bodies allows the detection of the early antigens breast
cancer in an anticipated (predictive) manner by means of
immunoassay, achieving this recognizing regardless of the
immunosuppressive environment.
Results and discussion
The images in Figure 1 of the 2D-immunoblots shows a re-
markable variation among the humoral immune response
mediated by IgG or IgM in each serum of individual female
mice at t = 0 and during the 5 weeks of development of
breast cancer. The number of antigens recognized by IgM
in the first week was very similar that recognized in time 0
(518 and 563, respectively); however, the recognition pattern
was different. In the analysis of IgM and IgG response with
time, the Σ of IgM spots at t = 0 varied from 35 to 98 anti-
gens, with an average of 62.6 and a standard deviation (sd)
of 23.5 (Table 1). During the 5 weeks, the IgM response
varied on average from 57.6 spots in the first week to 55.8
by the fifth week, with the lowest response (41 spots) in
the third week. After challenge with 4 T1 tumor cells, the
response IgG was, on average, the highest response at the
first week (20.3 spots), but this was decreased with time. It
can also be seen that 4 T1 antigen recognition by IgM is
presented from week 0 (pre-immune serum), whereas
there was no response of IgG (e.g. mice 1 and 2) or almost
absent (e.g. mice 4 and 5). At 1 week after implantation of
4 T1 tumor cells, the IgG and IgM responses were still
present; however, IgG recognition decays through to 5weeks of tumor growth, so that the response of IgM is
maintained at a higher level than IgG during tumor devel-
opment. Decrease in the IgG response is possibly due to
immunosuppression caused by the development of breast
cancer at the time that the 4 T1 tumor cells were im-
planted [5]. Since the IgM response, also declined slightly
in the number of spots with time, immunosuppression
would also be affecting it. Decrease in the IgM response
could be due to a T-independent immunosuppression,
which is based on the existence of T-independent antigens
as glycoproteins and glycolipids, which are recognized by
natural IgM because they are capable of activating B cells
without T cell collaboration [20-22]. Since the volume of
serum was low, IgM could not be measured by ELISA be-
cause of even though fewer spots, the IgM concentration
could be maintained, and then there would not be any
immunosuppression.
At time 0, the difference in spots number between the
IgG and IgM was clear, with the IgG spots being almost
zero, and the IgM spots numerous. The pattern of spots in
the IgM response at was highly variable, and there were no
2 similar immunoblots. Identification of 4 T1 antigen by
IgM, even before antigenic challenge (t = 0), was consistent
with an innate humoral recognition mentioned above, na-
ture of this recognition being through structural patterns of
Toll-like receptors. Carbohydrates are the main structures
recognized, but there are also reports where the natural
IgM can recognize the carboxyl terminus of proteins [23].
There were 2 types of IgM found in normal conditions in
the circulation in mice. Natural IgM is mainly secreted by
B-1a CD5+ cells in the apparent absence of antigen stimula-
tion, which constitutes most of the circulating IgM [24],
whereas antigen-induced IgM is mostly produced by con-
ventional B (B-2) cells only after antigen stimulation [25].
Thus antibodies detected at time 0 are called natural anti-
bodies. Variability in the IgM response was manifested as
a pattern of spots that became a multibinomial variable of
0 and 1, which could represent a signature of the IgM or
IgG humoral immune responses (Figure 2); each signature
is therefore a measure of this variability. Each mouse has
an individual pattern of recognition, in this case to the
tumor antigenic background, manifested in tumor size
(Table 2). Thus each individual has a unique expression of
genetically determined natural IgMs (in number and cap-
acity of recognition). The possibility that this genetic deter-
mination does not recognize different tumors and their cells
in the same way, or that some individuals recognize some
kind of tumor better than others, is being investigated.
The cancer model we used did not allow us to establish
a relation between a natural IgM response and resistance
to tumor because this model was originally one for
studying metastasis. Another type of mouse model, where
diverse stages of cancer can develop will allow us to corre-
late natural IgM response with resistance.
Figure 1 Images of 2D-immunoblot of the immune response mediated by IgG and IgM in female mice analyzed with PdQuest
software. Images of T = 0 and w1-5 are shown. Scales of Molecular Weight (Kda) and isoelectric point (pH) are only shown in the images of
2D-immunoblot 1_IgG-T = 0. The red crosses indicate the center of each spot and the yellow circle, their area.
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Table 1 Number, sum, average, standard deviation and total of spots found in 2D-immunoblot images of female mice
from response mediated by IgG and IgM through the development of breast cancer with 4 T1 tumor cells
Spots IgM
N° female mice w0 w1 w2 w3 w4 w5 ∑ spots IgM T = w1–w 5 TOTAL ∑ spots IgM w0 – w5
1 86 20 129 83 146 75 453 539
2 39 77 49 49 60 89 324 363
3 65 66 41 18 24 31 180 245
4 45 94 22 24 36 15 191 236
5 98 69 63 91 61 13 297 395
6 89 21 23 23 14 23 104 193
7 45 28 19 14 70 144 275 320
9 35 120 109 17 15 43 304 339
10 61 23 47 46 78 69 263 324
∑ spots by serum 563 518 502 365 504 502 2391 2954
Average 62.6 57.6 55.8 40.6 56.0 55.8 265.7 328.2
SD 23.6 36.4 39.0 29.2 41.4 43.0 100.1 102.5
Spots IgG
N° female mice w0 w1 w2 w3 w4 w5 ∑ spots IgG T =w1–w 5 TOTAL ∑ spots IgG w0-w5
1 0 27 9 0 0 2 38 38
2 0 8 8 5 0 0 21 21
3 0 0 3 5 0 0 8 8
4 4 3 8 2 11 5 29 33
5 4 34 13 2 1 1 51 55
6 7 10 14 5 1 10 40 47
7 2 30 21 5 11 12 79 81
9 6 51 46 15 11 15 138 144
10 7 20 25 17 14 21 97 104
∑ spots by serum 30 183 147 56 49 66 501 531
Average 3.33 20.33 16.33 6.22 5.44 7.33 55.67 59.00
SD 2.96 16.73 13.06 5.85 6.06 7.55 41.53 43.38
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4 T1 cells is not only caused by acquired immune re-
sponse, but by the innate immune response. Some anti-
gens that are recognized in the first week are also
recognized by the same female at time 0. It is possible
that these antigens in the first week, and sharing IP and
MW with time = 0, are a product of an adaptive IgM in
response to 4 T1 cells. The number of spots in Table 1
from the first to the fifth week for each mouse is the result
of subtracting the antigens recognized at t = 0, which by
coincidence were also detected in subsequent times of
tumor development by isoelectric point and molecular
weight determinations. Hence, in Table 1 the spots exclu-
sively produced by the innate immune response (t = 0),
separated from the spots produced exclusively by the ac-
quired immune response (t = w1-5), antigens that are
shared over time, were not considered exclusive. The sig-
nificant number of antigens was recognized by IgM at thefirst week, from which we could use several antigens for
early diagnosis because they are the first to be recognized
by IgM and IgG immunoglobulins after antigen challenge
with 4 T1 tumor cells. However, the antigens that are
mainly recognized are the one that overlapped between
t = 0 and w1 (Figure 1, Table 1). This overlap in the recog-
nition of antigens between natural and adaptive IgM makes
it difficult to use adaptive IgM as a diagnostic character of
early immunodiagnostic. This difficulty could be overcome
if technically one can distinguish structurally between
natural IgM and adaptive IgM.
The number of spots in each 2D-immunoblot by im-
munoglobulin to the week of tumor development was esti-
mated. Figure 3 gives frequency of spots of most of the
antigens recognized, those half recognized and those
barely recognized. The sum total of the spots of antigen
recognition by natural IgM in the T = 0 was 563, and the
frequency of spots for 8 antigens shared by all females
Figure 2 Development of a multibinomial signature based in the arrangement of spots in a 2D-immunoblot image, which was divided
in cells. A “1” was placed in cells that had a one o more spots, while a “0” was placed, when there were not spots.
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was 518, and the frequency of spots related to 10 shared
antigens. However, by comparing the frequency of antigen
recognition spots at T = 0 and T =w1, this was low, with
only 10 antigens shared between the two from a total of
1081. With respect to above mentioned IgM, the IgG re-
sponse was reduced in the first week (T =w1), but the fre-
quency of antigens recognized was similar between the
IgG and IgM responses, being 3 from 183 and 10 from
518 shared antigens between individuals, respectively. The
frequency of recognition of IgM and IgG against the same
antigens shows that there are very few antigens detected
by IgM or IgG shared among the individuals at time 0 and
week 1, or between IgG and IgM. But the fact that IgMTable 2 Tumor size in centimeters and volume of each
female mouse, with classification according to size: small
(1-1400 mm3), medium (1401-2800 mm3) and large
(2801-4200 mm3)
Size of tumors
N° female mice Size (cm) Volume (mm3) Category
1 1.8-1.5 2025 Medium
2 2.0-1.6 2560 Medium
3 1.0-0.7 245 Small
4 1.0-0.9 405 Small
5 0.8-0.6 144 Small
6 1.7-1.3 1436 Medium
7 2.2-1.9 3971 Large
9 1.2-2.0 600 Small
10 2.0-1.9 3610 Large
Average 1666.28
SD 1463.52and IgG match some antigens in w1 that are the early
antigen recognized indicates that they are particularly re-
markable; this antigenic “selection” by the host could be
used as a criterion to determine antigens in further work.
This shared recognition reinforces the idea of using this
system to find antigens in the human population that have
dual recognition, not only IgM (natural or adaptive) but
IgG, which can be help develop an early diagnostic test.Conclusion
IgM and IgG responses against 4 T1 cells vary with the
time and between individuals. Spots variation in 2D pat-
tern for natural IgM can be expressed as a binomial sig-
nature, which opens the way to correlate a particular
pattern with resistance or susceptibility. The possibility
of differentiating between adaptive IgM antibodies from
the natural IgMs should allow the study of the adaptive
IgM as a tool for early immunodiagnosis.Methods
Mice and cell line
10 female BALB/c AnN mice 8 old-weeks were kept in
the animal facilities at the Instituto de Investigaciones Bio-
médicas, UNAM. All experiments were carried out in ac-
cordance with the animal-welfare ordinance and approved
by the Code of Ethics for Academic Staff of the Institute:
(http://www.biomedicas.unam.mx/_administracion/regla-
mentos_formatos/archivos_pdf/CodigoIIBO.pdf).
The 4 T1 tumor cell line was grown in RPMI +10%
Fetal Bovine Serum +1 X of antibiotic-antimycotic mix-
ture (streptomycin, ampicillin) in culture dishes (25 cm2)
incubated at 37°C in air plus 5% CO2.
Figure 3 Frequency of spots found in each 2D-immunoblot images of female mice in T = 0 and w1 of response mediated by IgG and
IgM. Figure shows the isoelectric point and molecular weigth of spots that are shared not only among images of each time (T = 0 and T = w1),
but also among all female mice. Spots in red color are recognized “Half” and spots in blue heavy color are recognized “Vastly” by mice. Spots are
recognized by 0 to 1 mice were categorized as “Barely”, by 2 to 5 mice as “Half” and by 6 to 10 mice as “Vastly”. Ags = antigens.
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BALB/c mice was shaved on the abdomen and injected
with 10 × 103 4 T1 tumor cells in 50 μL isotonic solution
subcutaneously in a nipple of a mammary gland. The
tumor was allowed to develop and grow for 30 days. Tumor
size was measured after removal in 2 perpendicular dimen-
sions with a Vernier caliper. Tumor size in cubic millime-
ters was calculated by the formula (a x b2)/2, where b was
the smaller dimension of the tumor.
Serum sampling
BALB/c mice were bled by the tail once per week for 6
weeks. The first bleeding was made before implanting
4 T1 tumor cells (time = 0) or pre-immune serum. After
implantation of tumor cells, mice were bled and the sera
weekly (w1, 2, 3, 4 and 5). Blood was incubated at 4°C
for 30 min and centrifuged for storage at-20°C until use.
2D electrophoresis
For immunoblotting, proteins from 4 T1 cells were incu-
bated with Abs from each serum of every mouse at differ-
ent stages of tumor growth. A volume (100 μg) of 4 T1
cell proteins in 6 M urea, 50 mM DTT, 2% CHAPS, 2%
ampholines pH 3-10 (Bio-Lyte), 0.001% bromophenol blue
and MilliQ H2O up to 125 μL was used to hydrate the
IPG strips (7 cm) in an immobilized pH gradient (pHi 3-
10, Bio-Rad). To separate proteins from the 4 T1 cells ortumors in one dimension (isoelectric point), hydrated
strips were placed in the Protean IEF Cell from Bio-Rad
reaching a voltage of 4000 and 10,000 V-h, ~6 h.
After separation of proteins by isoelectric focusing, the
strips were equilibrated with 2 washes for 10 min, the
first in 6 M urea, 0.375 M Tris–HCl, pH8.8, 2% SDS,
20% glycerol, 2% (w / v) DTT, and the second in 6 M
urea, 0.375 M Tris–HCl, pH8.8, 2% SDS, 20% glycerol,
2.5% (w / v) iodo-acetamide.
For the separation in a second dimension (2D) for
molecular weight, the strip with separated proteins in
one dimension was placed on an acrylamide gel (Mini-
PROTEAN TGX Precast Gels, 10-20%, Bio-Rad) and
electrophoresed in buffer 25 mMTris pH 8.3, 250 mM
glycine, 0.1%SDS, at 100 V for 90 min in a chamber
(Mini-Protean Tetra Cell, Bio-Rad).
The proteins separated on 2D were electrophoretically
transferred to a nitrocellulose membrane using a wet trans-
fer chamber (Mini Trans-Blot Cell, Bio-Rad) at 100 V, 1 h
and 10 min; the buffer was Tris-Glycine-Methanol
(25 mMTris pH 8.3, 250 mM glycine, 20% v/v methanol).
After transfer, the membrane was placed in 20 mL
Sensitizer (12 mM HCl) for 5 min, and the solution was
removed. It was placed in 20 mL CPTS dye ((Copper(II)
phthalocyanine-3,4′,4″,4‴-tetrasulfonic acid tetrasodium
salt (50 mg in 100 mL 12 mM HCl)), and was stirred
strongly for protein staining. The dye was removed and
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lized with a scanner (HP Scanjet G4050). The stained pro-
teins were removed with Eraser solution (50 mL 0.2 M
KCl + 40.8 mL 0.2 M NaOH, pH 12.5).
ImmunoBlot
The nitrocellulose membrane was blocked with 30 mL 5%
non-fat dry milk in PBS + Tween 20 (0.03%) at pH 7.4 and
stirred overnight at 4°C. The next day the milk was re-
moved and 5 mL skim milk in PBS-Tween and the pri-
mary Ab mouse serum (1:250) were placed and stirred for
4 h at room temperature. Four washes each for 10 min
each of 20 mL PBS-Tween were use.
Bound antibodies were detected by incubation (1 h at
room temperature) with HRP-conjugated secondary anti-
body (goat anti-IgG or IgM mouse, ZIMED), diluted 1/
2500 in PBS-Tween 20. Each was washed 4 times for
10 min with 20 mL PBS-Tween. Detection of second anti-
body binding was by incubation with DAB substrate (3, 3′-
diaminobenzidine; 0.5 mg/mL; 10 min) and 10 μL hydrogen
peroxide.
Image processing
From duplicates of the resulting 2D-immunoblot images,
a master image was created, which was analyzed by
counting the total number of spots (Σspots) or the num-
ber of unique spots per week were counted. Exclusive
spots were obtained by subtracting the antigens recog-
nized at t = 0, which had coincidence in isoelectric point
and molecular weight, and were also detected at subse-
quent weeks of tumor development. Immunoblots were
digitalized using an HP Scanjet G4050 scanner with a
resolution level of 300 DPI in a TIFF format. The TIF
images were transformed to the Format 1.sc, required
for analysis in PDQuest software (Bio-Rad). The images
were transferred to Adobe Photoshop for counting of
spots, identification of coordinates of each spot in the
2D-immunoblot, and the calculation of the perimeters of
the spots, location of the coordinates and the centroids.
All 2D-immunoblots were analyzed at the same settings
of brightness, contrast, and color to minimize bias.
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